Patient Adherence to Fecal Calprotectin Testing Is Low Compared to Other Commonly Ordered Tests in Patients With Inflammatory Bowel Disease-Reference-Cited by-同舟云学术

Patient Adherence to Fecal Calprotectin Testing Is Low Compared to Other Commonly Ordered Tests in Patients With Inflammatory Bowel Disease

Published:2021-06-16 Issue:3 Volume:3 Page:
ISSN:2631-827X
Container-title:Crohn's & Colitis 360
language:en
Short-container-title:

Author:

Khakoo Nidah S¹^ORCID,Lewis Ayanna²,Roldan Giovanni A¹,Al Khoury Alex²,Quintero Maria A²,Deshpande Amar R²,Kerman David H²,Damas Oriana M²,Abreu Maria T²

Affiliation:

1. Department of Medicine, University of Miami School of Medicine, Miami, FL, USA

2. Division of Digestive Health and Liver Diseases, University of Miami Miller School of Medicine, Miami, FL, USA

Abstract

Abstract Background Limited data exist on adherence to fecal calprotectin (FCP) testing in patients with inflammatory bowel disease. Methods Completion rates for patients who had at least one FCP test ordered (n = 3082) and a subgroup with C-reactive protein, complete blood count, and Clostridium difficile tests also ordered (n = 1563) were analyzed. Results More patients completed blood than stool tests, with FCP having the poorest adherence of all tests analyzed. Older patients had higher FCP completion rates. No differences were noted in completion rates across age, gender, or ethnicity for blood tests. Conclusions Further studies are needed to develop strategies that improve the uptake of FCP.

Publisher

Oxford University Press (OUP)

Subject

Gastroenterology

Link

http://academic.oup.com/crohnscolitis360/advance-article-pdf/doi/10.1093/crocol/otab028/38657822/otab028.pdf

Reference17 articles.

1. Fecal calprotectin in diagnosis and clinical assessment of inflammatory bowel disease;Sipponen;Scand J Gastroenterol,2014

2. C-Reactive protein, fecal calprotectin, and stool lactoferrin for detection of endoscopic activity in symptomatic inflammatory bowel disease patients: a systematic review and meta-analysis;Mosli;Am J Gastroenterol.,2015

3. Fecal calprotectin use in inflammatory bowel disease and beyond: a mini-review;Alibrahim;Can J Gastroenterol Hepatol.,2015

4. The use of fecal calprotectin as a biomarker in gastrointestinal disease;Burri,2014

5. Low fecal calprotectin correlates with histological remission and mucosal healing in ulcerative colitis and colonic Crohn’s disease;Zittan;Inflamm Bowel Dis,2015

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Imaging in Inflammatory Bowel Disease;Rheumatic Disease Clinics of North America;2024-08

2. Development of Luminescent Biosensors for Calprotectin;ACS Chemical Biology;2024-06-06

3. The Management of Postoperative Recurrence in Crohn’s Disease;Journal of Clinical Medicine;2023-12-25

4. Results and lessons learned from the sbv IMPROVER metagenomics diagnostics for inflammatory bowel disease challenge;Scientific Reports;2023-04-18